top of page

From Worms to Workstreams: How Ora Biomedical Is Scaling AI Driven Longevity Discovery

Updated: Jul 30


Mini StartUp Review & Example for Fractional BD Opportunity

By Henning Mann, PhD | HM.BioConsulting3–5 minute read


Download the File

“Longevity research is evolving. AI and automation are accelerating drug discovery. In this space Ora Biomedical is one to watch.”


From Worms to Workstreams:

How Ora Biomedical Is Scaling AI‑Driven Longevity Discovery

 

Mini StartUp Review

 

Henning Mann, PhD, HM.BioConsulting

 

Background: Aging as a Modifiable Endpoint

 

Aging is the single greatest risk factor for most chronic diseases, yet for decades, drug discovery pipelines have focused on treating symptoms rather than addressing upstream biological aging itself. Today, we see more and more technologies emerging that can contribute to changing that approach.

 

Ora Biomedical, a Seattle-based biotech company launched in 2022, is at the forefront of this shift. By applying automation, AI, and deep geroscience to high-throughput screening in C. elegans, Ora is enabling faster, more predictive discovery of interventions that beneficially impact the molecular biology of aging. These have the potential not only to treat acute diseases driven by aging but also to slow or even reverse the decline of injury recovery and repair.

 

 

At HM.BioConsulting, we recognize Ora’s platform as a high-leverage opportunity for strategic business development, partnership building, and portfolio alignment in the rapidly evolving longevity biotech sector.

 

Innovative Approach: Ora Biomedicals’ Platform

Ora Biomedical’s core technology, WormBot‑AI, is an integrated platform combining:

 

  • Automated robotic workflows for large-scale organism handling

  • Real-time phenotypic tracking through computer vision

  • Neural network-based analytics to assess lifespan, movement, and healthspan metrics

  • Phenotype-first discovery in live animals that mitigates the in vitro to in vivo translational “valley of death”

At its foundation is the nematode Caenorhabditis elegans, a widely validated model for studying aging. With a short lifespan and conserved genetic pathways, C. elegans provides a powerful and cost-efficient system for early-stage drug and nutraceutical screening.

 

Ora’s leadership team is headed by Dr. Ben Blue, CEO, and Dr. Blair (Yan Ting) Zhao, CSO—alongside co-founders Dr. Mitchell Lee, Dr. Matt Kaeberlein (Chair), Dr. Brian Kennedy, Dr. Jan Gruber, and Dr. Jason Pitt (WormBot inventor). Together they combine deep academic expertise in geroscience with a translational and commercial focus.

 

Impact in Today’s Research Landscape

 

Several concurrent trends make Ora’s approach especially relevant:

 

  • AI is reshaping preclinical discovery, but it lacks ground-truth data: Institutions like Scripps and companies like Gero are increasingly using AI models to predict and identify lifespan-extending compounds in silico. However, there is an unmet need in both the data on which to train these models and the system with which to test them.

  • Longevity biotech is gaining investor attention: 2024–2025 has seen a surge in funding for startups focused on healthspan, often featuring platforms that offer early-phase screening capabilities.

  • Pharma is exploring aging-linked indications: With growing interest in senoytics, mitochondrial rejuvenation, and immune aging, platforms that can de-risk early discovery are in demand.

Ora Biomedical’s WormBot‑AI uniquely bridges computational modeling and biological validation, helping to identify promising leads with greater confidence and speed.

 

Recent Developments (2024–2026)

 

Since its founding, Ora Biomedical has secured several notable milestones that validate both its platform and its expanding research mandate:

 

  • NIH SBIR Phase I Grant – EleGantry (September 2024): Ora was awarded a $324,240 SBIR Phase I grant through the NIH National Institute on General Medical Sciences (NIGMS) to develop EleGantry—a new software and hardware infrastructure designed to enhance reproducibility and rigor in C. elegans longevity research. The system integrates advanced imaging, ML-powered data collection, and automated reporting to reduce variability across experimental runs. Source: orabiomedical.com / lifespan.io (September 3, 2024)

  • AFWERX / U.S. Air Force SBIR Phase I Contract (May 2024): Ora was selected by AFWERX, the innovation arm of the Department of the Air Force, for a $75,000 SBIR Phase I contract to develop longevity-targeting therapeutics to protect astronauts and high-altitude pilots from space radiation and other physiological stressors. This work is grounded in Ora’s in vivo screening capabilities using C. elegans as a model for radiation-induced aging. Source: lifespan.io (May 29, 2024)

  • mTOR Inhibitor Screen Completed with Rapamycin Longevity Lab (2024–2025): In what Rapamycin Longevity Lab’s Krister Kauppi described as “the largest-ever lifespan analysis of 601 mTOR modulators,” Ora completed the full two-part crowdfunded screen in partnership with Rapamycin Longevity Lab. The project screened all 601 compounds in C. elegans using WormBot-AI, with lifespan data publicly released via Rapamycin Longevity Lab’s LID database. The screen identified several compounds outperforming rapamycin in lifespan extension, including a novel mTOR inhibitor now under follow-up development at Ora. Source: LinkedIn / Krister Kauppi (1 week ago); lifespan.io (May 1, 2025)

  • Combination Longevity Database Launch (2025): Ora launched V1 of its combination longevity interventions database, providing open access to screened two-way compound combinations. The company describes this as an early milestone toward completing the Million Molecule Challenge (MMC)—a five-year initiative to screen one million longevity interventions. As of 2025, Ora is conducting over 300,000 experiments per year via its WormBot-AI platform. Source: LinkedIn / orabiomedical.com (2025)

  • Leadership Update (2025): Dr. Benjamin Blue, previously CTO and a co-developer of the WormBot-AI machine learning pipeline, assumed the role of CEO. Dr. Mitchell Lee, founding CEO, transitions to a strategic advisory and research role. Dr. Blair (Yan Ting) Zhao joined as Chief Scientific Officer, bringing expertise in vascular biology, regenerative medicine, and synthetic design proteins. Source: orabiomedical.com/team; Siim Land Podcast (March 2026)

 

  • Extropy Ventures Investment (2025): Berlin-based Extropy Ventures GmbH announced an investment in Ora Biomedical, citing the WormBot-AI platform’s unique ability to match the accelerated pace of AI-driven predictions with rapid biological validation. Extropy’s announcement specifically highlighted Ora’s parallel work on mTOR inhibitor screening and radiation-protective therapeutics as evidence of its broad translational range within the longevity field. Source: LinkedIn / Extropy Ventures GmbH (approx. 2 months ago)

  • Moves to CoLabs Seattle – Seattle South Lake Union (May/June 2025): Ora Biomedical officially relocated to CoLabs Seattle, a next-generation life sciences incubator in Seattle’s South Lake Union biotech hub. The move was announced on LinkedIn as a strategic step—providing state-of-the-art laboratory infrastructure, shared core facilities, and proximity to the Pacific Northwest’s most active biotech community. Source: LinkedIn / Ora Biomedical, Inc. (3 weeks ago)

  • AIxLongevity NYC Pitch Prize & Biolabs@NYULangone Expansion (June 2026): CEO Dr. Ben Blue won a pitch competition prize at the AIxLongevity event in New York City, organised by Longevity Global. The win was accompanied by an announcement that Ora Biomedical is expanding its geographic footprint into New York City through Biolabs@NYULangone—placing the company within one of the most influential biotech ecosystems in the US. The company described 2026 as a pivotal year for growth and visibility in the longevity space. Source: LinkedIn / Ora Biomedical, Inc. (2 days ago); Ben Blue (4 days ago)

 

Summary:

Ora Biomedical’s WormBot‑AI platform represents both a novel approach to aging research and, more importantly, a broader transition toward scalable, data-rich discovery systems that enable actionable therapeutic insights.

 

As the longevity sector continues to mature, companies that successfully combine automation, AI, and biologically validated models will be best positioned to drive both scientific and commercial outcomes.

 

Outlook:

 

The trajectory for Ora Biomedical looks very positive. With the completion of the largest-ever mTOR inhibitor screen in C. elegans, a newly secured investor in Extropy Ventures, a state-of-the-art laboratory home at CoLabs Seattle, and a pitch prize at AIxLongevity in New York City now opening doors at Biolabs@NYULangone, Ora is transitioning from promising early-stage platform to credible longevity research biotech. The Million Molecule Challenge remains the centerpiece of its open science strategy: an ambitious, community-funded effort to build the world’s most comprehensive healthy aging therapeutics database, and the pace at which the platform is delivering is beginning to attract strategic and financial attention that converts pipeline compounds into clinical candidates.

 

From the perspective of HM.BioConsulting, this phase or Ora Biomedical is very exciting and we will keep following them closely. Our work at the intersection of New Approach Methodologies, drug discovery, and life sciences business development has given us a front-row view of how platforms like WormBot-AI are quietly redefining what early-stage longevity drug discovery looks like. Their intent to be rooted in validated biology, designed for scale, and now gaining cross-sectoral recognition from investors, government agencies, and the research community alike (C. elegans may be a humble organism, but as a NAM it is fast, cost-effective, biologically informative, and scalable, and it is proving to be one of the most powerful tools available to the field. Ora Biomedical is the company making the most of that potential. We look forward to watching, and where possible supporting, what comes next.

 

 

Learn more:

 

Ora Biomedical – Platform & Science: https://orabiomedical.com/science/

Ora Biomedical – Company Overview: https://orabiomedical.com/company/

Million Molecule Challenge – Sponsor a Test: https://orabiomedical.com/sponsor-mmc/

Ora Biomedical: Accelerating Drug Discovery for Geroscience (PMC/Geroscience, Dec 2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC11690787/

 

@KristerKauppi @mkaeberlein @biogerontology @agingdoc1 @pumpdotscience @beappbeapp

 
 
 

Comments

bottom of page